GlassScriptPhysician profile
Sarma S Challa
NPI 1699776286
$5,134.98
in general payments reported to CMS, 2019-2025
30 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $538 · 2021: $837 · 2022: $1,144 · 2023: $672 · 2024: $560 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $578.90 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.58 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $527.62 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $496.53 | 2019-2025 | Lifevest |
| Pfizer INC. | $481.41 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $345.39 | 2019-2024 | Xarelto |
| Amgen INC. | $307.45 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $260.11 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $243.49 | 2019-2023 | Eliquis |
| Abbott Laboratories | $216.90 | 2020-2024 | Aveir |
| Esperion Therapeutics, INC. | $201.90 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $191.71 | 2019-2024 | |
| Erbe USA INC | $160.73 | 2024 | |
| Medtronic, INC. | $76.59 | 2022 | |
| Heartflow, INC. | $61.04 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.45 | 2021-2025 | |
| Bardy Diagnostics, INC. | $50.00 | 2019-2020 | |
| Boston Scientific Corporation | $49.80 | 2020-2023 | Ekosonic, Watchman Access System |
| Shockwave Medical, INC | $42.32 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $33.43 | 2023 | Inpefa |
| Cvrx, INC. | $32.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.16 | 2019-2021 | |
| Genzyme Corporation | $25.44 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.44 | 2019 | |
| Zoll Circulation INC | $20.45 | 2021 | |
| Scpharmaceuticals INC. | $17.53 | 2024 | |
| Cardinal Health 200 LLC | $17.13 | 2019 | |
| Gilead Sciences, INC. | $13.30 | 2019 | |
| Chiesi USA, INC. | $13.17 | 2021 | |
| Cardiovascular Systems INC. | $5.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarma Challa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.